Platinum-based doublet chemotherapy was historically the standard first-line treatment for patients with recurrent or metastatic non-small cell lung cancer (NSCLC), whose tumors lack epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations. Here, ALK is linked to non-small cell lung carcinoma.